Yes, Antabuse (disulfiram) is still FDA-approved, actively manufactured, and prescribed for alcohol use disorder in the United States. It remains on the market more than 70 years after its initial approval, making it the oldest medication specifically designed to discourage drinking. That said, its role has shifted considerably. It’s no longer a first-line treatment in most clinical settings, having been largely overtaken by newer medications like naltrexone and acamprosate that work differently in the brain. But for certain patients, particularly those with strong motivation and a support system to ensure they take it consistently, Antabuse still has a place in treatment.
How Antabuse Works
Antabuse doesn’t reduce cravings or block the pleasurable effects of alcohol the way newer medications do. Instead, it acts as a chemical deterrent. The drug interferes with your body’s ability to break down alcohol fully, causing a buildup of a toxic byproduct called acetaldehyde. If you drink while taking it, you’ll feel genuinely ill within about 10 minutes: flushing, sweating, headache, nausea, vomiting, heart palpitations, and confusion. The reaction can last for several hours.
The idea is simple. Knowing that even a single drink will make you sick creates a powerful daily reason not to pick one up. This makes the decision not to drink feel automatic rather than something you have to white-knuckle through every time you’re tempted. Even after you stop taking the medication, a reaction to alcohol can still occur for up to two weeks.
Why It Fell Out of Favor
Antabuse’s biggest limitation is that it only works if you actually take it. Unlike naltrexone, which reduces the rewarding feeling of alcohol in your brain, or acamprosate, which helps stabilize brain chemistry during early sobriety, Antabuse does nothing to address the underlying drive to drink. A person who decides they want to drink can simply stop taking the pill and wait a couple of weeks.
Unsupervised use has historically shown disappointing results for this reason. Compliance drops off quickly when patients are left to take it on their own. A review in The British Journal of Psychiatry also raised questions about the standard dose’s reliability: among 63 patients taking disulfiram under supervision who then consumed alcohol, only about half had a significant physical reaction at the typical daily dose of 200 to 300 milligrams. This means some people could drink on it without getting very sick, which undermines the entire premise.
Safety concerns also play a role. Antabuse can stress the liver, and since many people with alcohol use disorder already have some degree of liver damage, that creates a real tension. Liver function tests are typically checked before starting the drug and then monitored at two and four weeks. The medication is also problematic for people with heart disease, severe lung conditions, seizure disorders, diabetes, kidney disease, or serious mental health conditions like depression or psychosis, because the alcohol reaction can worsen all of these.
When It Still Gets Prescribed
Despite these drawbacks, Antabuse has a specific niche where it performs well: supervised administration. When a spouse, family member, employer, or clinic staff member watches the person take the pill each day, compliance is no longer optional. In these structured arrangements, the medication works as intended. It removes the daily internal debate about drinking by making the consequences immediate and physical rather than abstract.
It’s also sometimes used for people who haven’t responded to naltrexone or acamprosate, or who prefer a deterrent-based approach because they find the psychological “guardrail” helpful. Some specialty treatment programs, drug courts, and occupational health programs (for pilots, physicians, or other professionals with licensing requirements) incorporate supervised Antabuse as part of a monitoring agreement. An early pilot study even found that disulfiram was twice as effective as naltrexone at reducing alcohol intake among people who also used cocaine, suggesting it may have advantages in specific populations.
What Taking It Looks Like
Treatment typically starts with a higher loading dose of around 800 milligrams daily for the first two to three days, then tapers down to a maintenance dose of 100 to 200 milligrams per day. The pill is taken once daily, usually in the morning. There’s no intoxicating or mood-altering effect from the drug itself. You won’t feel anything different on the days you don’t drink.
You do need to be careful about hidden sources of alcohol. Certain cough syrups, mouthwashes, cooking wines, and even some vinegar-based sauces contain enough alcohol to trigger a mild reaction. Most prescribers will walk you through what to avoid. Blood work to check liver enzymes is standard both before and during treatment, since the drug can occasionally cause liver inflammation independent of any alcohol reaction.
How It Compares to Other Options
The three FDA-approved medications for alcohol use disorder each work through a completely different mechanism, and they aren’t interchangeable. Naltrexone blocks the brain’s reward response to alcohol, making drinking feel less satisfying. Acamprosate helps ease the persistent anxiety, restlessness, and sleep disruption that many people experience for months after quitting. Antabuse, by contrast, does nothing to change how alcohol feels or how your brain recovers. It simply punishes drinking with physical illness.
This makes Antabuse a better fit for someone who has already committed to sobriety and wants a concrete enforcement tool, rather than someone who is still ambivalent about quitting. It pairs well with counseling and support groups, since the pill handles the behavioral temptation while therapy addresses the deeper patterns driving the drinking. In practice, many addiction specialists view it as one tool in a larger kit rather than a standalone treatment.
Prescribing rates vary dramatically by country. Data from the mid-1990s showed that Scandinavian countries, particularly Denmark, used disulfiram at rates roughly 12 times higher than the United States per capita. The U.S. and the UK sat near the bottom of the list. That pattern largely persists, reflecting different treatment philosophies across healthcare systems. In the U.S., naltrexone and acamprosate now receive more prescriptions overall, but Antabuse remains actively manufactured by Norwich Pharmaceuticals and distributed by Alvogen, with no signs of discontinuation.